During the afternoon session on Wednesday 7 March, Shayesteh will be giving a presentation on the role of regulatory affairs in product development and in communication with healthcare authorities. In her talk, she will outline the key role that regulatory affairs plays in innovation and the approach companies require for a successful regulatory strategy.
“I aim to shed light on some of the key developments in the field of regulatory affairs that affect companies in the life sciences sector,” commented Shayesteh. “Entrepreneurial companies must adopt a solid regulatory strategy if they wish to succeed in bringing innovative products to the market and satisfy unmet medical needs.”
Shayesteh is the Managing Director and founder of SFL. She has comprehensive experience in formulating global regulatory strategies and provides support for the development of drugs, orphan drugs, drug and device combination products, borderline products, medical devices, in vitro diagnostics and advanced therapy medicinal products.
Shayesteh is Chair of the Combination Products Topic Group at EuropaBio. She has been member of the Program Committee of DIA EuroMeeting for 2011, 2012 and 2013 leading the Theme Drugs, Devices, In Vitro Diagnostics and their Combinations. In 2012 she received the Open University Business School’s Alumni Award Outstanding Contribution to an Organization.
